|本期目录/Table of Contents|

[1]赵磊,曹邦伟.胃癌靶向治疗的成与败[J].慢性病学杂志,2014,(08):590-595.
点击复制

胃癌靶向治疗的成与败(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2014年08期
页码:
590-595
栏目:
述评
出版日期:
2014-11-30

文章信息/Info

Title:
-
作者:
赵磊; 曹邦伟
首都医科大学附属北京友谊医院肿瘤科，北京100050
Author(s):
-
关键词:
胃癌; 靶向治疗; 临床试验
Keywords:
-
分类号:
R735.2
DOI:
-
摘要:
目前， 胃癌是全球癌症死亡的第二大原因。虽然医疗可以改善进展期胃癌（advanced gastric cancer， AGC） 患者的生活质量和延长患者生存期，但在过去二十年中，胃癌的治疗并没有取得显著的进展。 因此，AGC 最优的标准一线化疗方案仍是有争议的，而且大多数化疗药物的作用是局部和短期的，疾病晚 期患者的预后非常差，中位存活期仅为12 个月，只有10%的患者生存期可以超过2 年。Trastuzumab 以及 最近的Ramucirumab 所获得的生存改善， 证明靶向和生物治疗的前景， 以及胃癌中分子肿瘤特征的重要 性。本文回顾了胃癌中最常发生的基因改变，总结了胃癌治疗中获得成功以及研究失败的靶向药物，并且 强调了正在进行的试图将生物知识转化为改善临床结局的研究，以引起业界对这些研究结果的关注。
Abstract:
-

参考文献/References:

[1] Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5- fluorouracil, doxorubicin, and methotrexate in ad? vanced gastric cancer ［J］．Cancer, 1993,72(1):37-41.
[2］ Pyrhonen S,Kuitunen T,Nyandoto P,et al. Randomised com? parison of fluorouracil, epidoxorubicin and methotrexate (FEM ? TX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer ［J］． Br J Cancer, 1995,71 (3):587-591.
[3］ Cunningham D, Okines AF, Ashley S. Capecitabine and oxali? platin for advanced esophagogastric cancer ［J］．N Engl J Med, 2010,362(9):858-859.
[4］ Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first- line therapy for advanced gas? tric cancer: a report of the V325 Study Group ［J］．J Clin On? col, 2006,24(31):4991-4997.
[5］ Hynes NE, Lane HA. ERBB receptors and cancer: the com ? plexity of targeted inhibitors ［J］．Nat Rev Cancer, 2005,5(5): 341-354.
[6］ Yarden Y, Sliwkowski MX. Untangling the ErbB signalling net? work ［J］． Nat Rev Mol Cell Biol, 2001,2(2):127-137.
[7］ Cabuk D, Basaran G, Celikel C, et al. Vascular endothelial growth factor, hypoxia- inducible factor 1 alpha and CD34 ex? pressions in early-stage gastric tumors: relationship with patho? logical factors and prognostic impact on survival ［J］．Oncolo? gy-Basel, 2007,72(1-2):111-117.
[8］ Juttner S, Wissmann C, Jons T, et al. Vascular endothelial growth factor- D and its receptor VEGFR- 3: two novel inde? pendent prognostic markers in gastric adenocarcinoma ［J］． J Clin Oncol, 2006,24(2):228-240.
[9］ Hanahan D,Weinberg RA.Hallmarks of cancer: the next gener? ation ［J］． Cell, 2011,144(5):646-674.
[10］ Matsumoto K, Arao T, Hamaguchi T, et al. FGFR2 gene am? plification and clinicopathological features in gastric cancer ［J］． Br J Cancer, 2012,106(4):727-732.
[11］ Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct ther?apeutic targets ［J］．Gut, 2012,61(5):673-684.
[12］ Su X, Zhan P, Gavine PR, et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large in? ternational multicentre study ［J］． Br J Cancer, 2014,110(4): 967-975.
[13］ Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib ［J］． J Clin Oncol, 2011,29(36):4803-4810.
[14］ Graziano F, Galluccio N, Lorenzini P, et al. Genetic activation of the MET pathway and prognosis of patients with high- risk, radically resected gastric cancer ［J］． J Clin Oncol, 2011,29 (36):4789-4795.
[15］ Lee J, van Hummelen P, Go C, et al. High- throughput muta? tion profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma ［J］．PLoS One, 2012,7(6):e38892.
[16］ Liu JF, Zhou XK, Chen JH, et al. Up- regulation of PIK3CA promotes metastasis in gastric carcinoma ［J］．World J Gastro? enterol, 2010,16(39):4986-4991.
[17］ Shi J, Yao D, Liu W, et al. Frequent gene amplification pre? dicts poor prognosis in gastric cancer ［J］．Int J Mol Sci, 2012, 13(4):4714-4726.
[18］ Shi J, Yao D, Liu W, et al. Highly frequent PIK3CA amplifi? cation is associated with poor prognosis in gastric cancer ［J］． Bmc Cancer, 2012,12: 50.
[19］ Klempner SJ, Myers AP, Cantley LC. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3- kinase pathway ［J］． Cancer Discov, 2013,3(12):1345-1354.
[20］ Yang WS, Moon HG, Kim HS, et al. Proteomic approach re? veals FKBP4 and S100A9 as potential prediction markers of therapeutic response to neoadjuvant chemotherapy in patients with breast cancer ［J］． J Proteome Res, 2012,11(2):1078- 1088.
[21］ Chae YK, Gonzalez- Angulo AM. Implications of functional proteomics in breast cancer ［J］．Oncologist, 2014,19(4):328- 335.
[22］ Lam SW, Jimenez CR, Boven E. Breast cancer classification by proteomic technologies: current state of knowledge ［J］． Can? cer Treat Rev, 2014,40(1):129-138.
[23］ Lin LL, Huang HC, Juan HF. Discovery of biomarkers for gas? tric cancer: a proteomics approach ［J］． J Proteomics, 2012, 75(11):3081-3097.
[24］ Wu JY, Cheng CC, Wang JY, et al. Discovery of tumor mark? ers for gastric cancer by proteomics ［J］． PLoS One, 2014,9 (1):e84158.
[25］ Torti D, Sassi F, Galimi F, et al. A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic in? hibition of the MET oncogene in gastric tumors ［J］．Int J Can? cer, 2012,130(6):1357-1366.
[26］ Lee J, Kim S, Kim P, et al. A novel proteomics- based clinical diagnostics technology identifies heterogeneity in activated sig? naling pathways in gastric cancers ［J］．PLoS One, 2013,8(1): e54644.
[27］ Slotta- Huspenina J, Wolff C, Drecoll E, et al. A specific ex? pression profile of heat- shock proteins and glucose- regulated proteins is associated with response to neoadjuvant chemothera? py in oesophageal adenocarcinomas ［J］． Br J Cancer, 2013, 109(2):370-378.
[28］ Fujimoto- Ouchi K, Sekiguchi F, Yasuno H, et al. Antitumor activity of trastuzumab in combination with chemotherapy in hu? man gastric cancer xenograft models ［J］． Cancer Chemother Pharmacol, 2007,59(6):795-805.
[29］ Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oe? sophageal junction cancer (ToGA): a phase 3, open-label, ran? domised controlled trial ［J］． Lancet, 2010,376(9742):687- 697.
[30］ Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab mono? therapy for previously treated advanced gastric or gastro- oe? sophageal junction adenocarcinoma (REGARD): an internation? al, randomised, multicentre, placebo- controlled, phase 3 trial ［J］．Lancet, 2014,383(9911):31-39.
[31］ Wadhwa R, Song S, Lee JS, et al. Gastric cancer- molecular and clinical dimensions ［J］．Nat Rev Clin Oncol, 2013,10(11): 643-655.
[32］ Catenacci DV, Henderson L, Xiao SY, et al. Durable complete response of metastatic gastric cancer with anti-Met therapy fol? lowed by resistance at recurrence ［J］．Cancer Discov, 2011,1 (7):573-579.
[33］ Sun W, Powell M, O'Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophage? al junction adenocarcinoma: ECOG 5203 ［J］． J Clin Oncol, 2010,28(18):2947-2951.
[34］ Satoh T, Yamada Y, Muro K, et al. Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S- 1 or capecitabine) in Japanese patients with previously untreated ad? vanced gastric cancer ［J］． Cancer Chemother Pharmacol, 2012,69(2):439-446.
[35］ Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxalipla? tin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open- label phase 3 trial ［J］．Lancet Oncol, 2013,14(6):481-489.
[36］ Dragovich T, McCoy S, Fenoglio- Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adeno? carcinomas: SWOG 0127 ［J］． J Clin Oncol, 2006,24(30): 4922-4927.
[37］ Rodriguez CP, Adelstein DJ, Rice TW, et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyper?fractionated radiation followed by maintenance gefitinib in lo? coregionally advanced esophagus and gastroesophageal junction cancer ［J］．J Thorac Oncol, 2010,5(2):229-235.
[38］ Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second- line treatment for advanced gastric cancer ［J］． In? vest New Drugs, 2011,29(6):1449-1458.
[39］ Moehler M, Mueller A, Hartmann JT, et al. An open- label, multicentre biomarker- oriented AIO phase II trial of sunitinib for patients with chemo- refractory advanced gastric cancer ［J］． Eur J Cancer, 2011,47(10):1511-1520.
[40］ Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first- line therapy in ad? vanced gastric cancer: a randomized, double- blind, placebocontrolled phase III study ［J］． J Clin Oncol, 2011,29(30): 3968-3976.
[41］ Shen L, Li J, Xu J, et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: random ? ized, double- blind, phase III study (AVATAR study) ［J］． Gastric Cancer, 2014.
[42］ Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer ［J］．PLoS One, 2013,8(3):e54014.
[43］ Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, dou? ble- blind, phase III GRANITE- 1 study ［J］． J Clin Oncol, 2013,31(31):3935-3943.

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2014-11-30